January 29, 2018 / 1:51 PM / 3 months ago

BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder

Reuters Staff

1 Min Read

Jan 29 (Reuters) - Abeona Therapeutics Inc:

* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA

* ABEONA THERAPEUTICS - CONTINUES TO ENGAGE FDA ON ITS PIVOTAL PHASE 3 CLINICAL TRIAL DESIGN, AND WILL PROVIDE AN UPDATE ON RMAT PROGRAM IN COMING MONTHS Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.